作者:赵颖洁丨王柯蓉丨毕允锴
在COINS拟议规则下的中国创新药跨境交易:20个典型场景与核心问题解答(上)以及COINS冲击中美创新药交易:20个典型场景和应对要点(下)中,我们结合20个典型交易场景,分析了美国财政部针对《全面对外投资国家安全法案》发布的拟议实施规则(“COINS拟议规则”)对中美之间的创新药投融资、License-out、Co-development、NewCo、CRO/CDMO等交易及存量业务的潜在影响、应对要点及合规边界。
我们理解,行业正在积极向美国财政部反馈意见,我们也收到了大量生命科学公司和投资机构就COINS拟议规则相关意见的咨询。在前两篇文章分析的基础上,结合对相关交易场景、行业实操情况及共性问题的进一步观察,我们在此提供英文版本的对拟议规则的11条意见,供相应市场主体参考。
1. Further Clarification on the Scope of Pharmaceutical Compounds. The Proposed Rule would cover a broad range of pharmaceutical compounds and their delivery mechanisms. The Treasury Department has specifically requested comment on whether and how the "pharmaceutical compounds" described in that provision should be more precisely scoped to focus on advanced or frontier technologies. We suggest that the Treasury Department further clarify the relevant technical criteria for determining which pharmaceutical compounds fall within that scope, thereby improving the clarity and predictability of the final regulations.
2. Further Clarification on Calculation of the 50% Equity Interest Threshold and the Treatment of ESOPs. We suggest that Treasury clarify whether the 50 percent equity interest threshold is calculated on an issued and outstanding basis or a fully diluted and as-converted basis, and specify how shares reserved under an ESOP but not yet granted, granted but unexercised options, and convertible securities are treated for purposes of that calculation. We further recommend that, as a general matter, the calculation be based on equity interests actually issued and outstanding, and that employee equity incentive awards and other contingent equity interests that do not confer a present equity interest on the holder not be automatically included in the calculation.
3. Distinguish Customary Investor Protective Rights from Actual Direction or Control. For an offshore biotech company in which Chinese shareholders collectively hold less than 50 percent of its equity interests, we suggest that the Treasury Department further distinguish customary protective rights of VC/PE investors from actual direction or control over the company's management or policies. For example, customary anti-dilution protections, preemptive rights, and veto rights over reserved matters that are designed to protect a shareholder's economic interests should not be deemed to confer such direction or control solely by virtue of their existence.
4. Further Clarification of the Boundary Between Arm's-Length CRO/CDMO Arrangements and Financial Dependency. Under proposed § 851.208(a)(8), a finding of financial dependency requires both satisfaction of the applicable financial threshold and the existence of a board seat, a voting or equity interest, or contractual power to direct or cause the direction of the management or policies of one or more covered foreign persons. Accordingly, the proportion of operating expenses paid to a service provider is not, standing alone, sufficient to establish financial dependency. We suggest that the Treasury Department include illustrative examples in the final regulations confirming that an offshore biotech company that engages an independent Chinese CRO or CDMO under an arm's-length services agreement would not be deemed a covered foreign person solely because the fees paid to that service provider exceed 50 percent of the offshore company's operating expenses, provided that the parties do not have any of the specified equity or management-control relationships. We further suggest clarifying that customary rights relating to project management, quality oversight, and acceptance of deliverables under a services agreement do not, without more, constitute contractual power to direct or cause the direction of the relevant service provider's management or policies.
5. Clarify the Definition of a Joint Venture and Exclude Qualifying Ordinary VC/PE Financings and NewCo Transactions from Its Scope. Where multiple independent financial investors subscribe for shares in an offshore NewCo under customary financing documents, or where a Chinese biotech company acquires a minority equity interest in an offshore NewCo in exchange for granting an IP license or transferring IP to the NewCo while a U.S. fund participates in the financing through a cash contribution, we suggest that the Treasury Department clarify that such transactions generally do not constitute a joint venture if the parties hold economic rights and investor protective rights solely in their capacities as shareholders and there is no separate arrangement providing for joint operations, joint control over a specific business, or the sharing of project operating losses, unless the parties have entered into another substantive joint venture arrangement or structured the transaction to evade the regulations.
6. Further Clarify the Boundary Between Co-Development Arrangements and Joint Ventures. We suggest that the Treasury Department distinguish contractual co-development collaborations from joint ventures involving the joint operation of a business. We further suggest clarifying that an arrangement should not be deemed to constitute a joint venture solely because it involves the contractual allocation of specified development costs, technical coordination or project oversight through a joint steering committee (JSC), or the receipt of milestone payments, royalties, or other consideration under a license agreement. The determination should instead be based on a holistic assessment of whether the parties jointly contribute resources to conduct a specific business, share its operating profits and losses, and exercise substantive joint decision-making authority over its operations.
7. Further Clarification of the Buyout Exception and Its Application to Cross-Border Acquisitions of Pharmaceutical Assets. The Proposed Rule provides an exception for certain complete acquisitions by a U.S. person of interests held by Covered Foreign Persons in entities or assets located outside a Country of Concern. We suggest that the Treasury Department provide illustrative examples and further guidance on how to determine the location of offshore companies, pharmaceutical intellectual property, and global development rights held by Chinese biotech companies, and on the types of transactions that qualify for the Buyout Exception under § 851.501(b). We further suggest clearly distinguishing an outright purchase of pharmaceutical IP from an acquisition of equity in an offshore entity, so that uncertainty regarding the subject matter of the transaction or the location of the relevant assets does not unnecessarily affect ordinary cross-border transactions involving innovative pharmaceutical assets.
8. Clarify the Distinction Between Commercial CRO/CDMO Prepayments and Investment-Like Funding. We suggest that the Treasury Department use illustrative examples to clarify that advance payments, capacity reservation fees, and equipment modification charges under an arm's-length services agreement do not constitute a covered national security transaction solely because a Chinese CRO or CDMO uses those amounts to construct or improve research and development or manufacturing facilities, provided that the U.S. company does not thereby acquire ownership of the facilities, equity-like economic interests, or joint operating rights, and does not otherwise directly undertake a transaction described in § 851.209(a)(5). This clarification would help preserve ordinary cross-border research, development, and manufacturing collaborations.
9. Clarify the Scope of "Maintain Operations" Under the Intracompany Transfer Exception and Permit Reasonable Expansion and Technological Upgrades of Existing Operations. The Treasury Department has requested comment on whether "maintain operations" should include capacity expansion and technological upgrades. We suggest adopting a relatively broad interpretation that would allow a U.S. parent company to provide funding to an existing Chinese WFOE for facility improvements, technological upgrades, efficiency enhancements, and the reasonable expansion of existing covered operations, provided that the WFOE does not, as a result, enter a new category of covered technology or move from a Notifiable Technology to a Prohibited Technology. We also suggest distinguishing between a Chinese biotech company using its own funds to undertake new activities and a U.S. investor making a new covered investment.
10. Consider an Exception for Ordinary Corporate Restructurings. Where a U.S. investor holds an investment made before the effective date of the final regulations and, as a result of a Chinese biotech company's unwinding of a red-chip structure or another ordinary commercial reorganization, is required to exit a Cayman Islands or other offshore holding vehicle and reacquire equity in the Chinese operating company, we suggest that the Treasury Department permit the investor to preserve its existing investment subject to reasonable conditions. The exception could apply where the restructuring does not increase the amount invested, the investor's ultimate economic interest, or its substantive governance rights, and is not intended to evade the regulations. Such a transaction restructures an existing investment rather than introducing additional U.S. capital into a sector involving a Notifiable Technology or Prohibited Technology and should therefore be distinguished from a genuinely new investment.
11. Consider a Reasonable Transition Exception for Binding Investment Agreements Signed Before, but Not Closed by, the Effective Date. The Proposed Rule provides transition protection for certain Binding, Uncalled Capital Commitments and certain contingent equity interests acquired before the effective date, but does not provide equally clear protection for legally binding equity investment or acquisition agreements signed before that date. We suggest that the Treasury Department permit such transactions to close in accordance with their original terms during a reasonable transition period. The exception could be subject to specific conditions, including that the agreement became legally binding before the effective date, the transaction is not intended to evade the regulations, and the parties do not materially increase the investment amount, expand the scope of the investment, or grant additional investor rights after the effective date. This approach would reduce the risk that ordinary commercial contracts become incapable of performance solely because of a regulatory change.
根据COINS拟议规则所列提交指引,书面意见须于2026年12月7日前送达美国财政部。提交时,请填写提交人姓名及组织名称(如适用),并注明“Outbound Investment Security Program Regulations”。
提交人可通过Federal eRulemaking Portal(Regulations.gov)电子提交。可直接进入https://www.regulations.gov/commenton/TREAS-DO-2026-0595-0001,填写简要说明并上传完整评论函及支持材料。所有评论、附件及支持材料均会公开,因此请勿提交不希望公开的个人信息或商业敏感信息。
注:本文依据截至2026年11月3日的COINS拟议规则及正式征求意见信息整理。拟议规则尚未生效,最终规则及提交安排仍可能调整。
特别声明 |
|
汉坤律师事务所编写《汉坤法律评述》的目的仅为帮助客户及时了解中国或其他相关司法管辖区法律及实务的最新动态和发展,仅供参考,不应被视为任何意义上的法律意见或法律依据。 如您对本期《汉坤法律评述》内容有任何问题或建议,请与汉坤律师事务所以下人员联系: |
|
赵颖洁 电话: +86 21 6080 0572 |